Seres Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $789,000 | $0 | $0 | $7.1M | $144.9M |
| Operating income | -$94.0M | -$121.3M | -$195.1M | -$179.9M | -$64.5M |
| Operating expenses | $94.8M | $121.3M | $195.1M | $179.9M | $209.4M |
| Cash from operations | $1.1M | -$148.6M | -$117.4M | -$228.8M | $6.7M |
| Capital expenditure | $252,000 | $380,000 | $8.0M | $9.8M | $9.6M |
| Free cash flow | $865,000 | -$149.0M | -$125.3M | -$238.6M | -$2.9M |
| Impairments | — | — | $0 | $0 | $0 |
| Total assets | $138.2M | $139.8M | $358.6M | $348.8M | $354.9M |
| Total liabilities | $94.0M | $126.0M | $403.5M | $338.0M | $223.4M |
Shares outstanding 9.6M · Free float 33.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.